JPO

Alnylam Pharmaceuticals this week announced that the Japanese Patent Office has upheld certain key claims within the company's Tuschl-II patent during invalidation proceedings initiated at the request of Bio Think-Tank, a Japanese company.

Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

The patent claims siRNAs containing proprietary 2’-O-methyl structures.

The patent covers a proprietary nucleic acid condensing and delivery peptide motif, as well as its use with therapeutic nucleic acids.

According to Alnylam, the patent "includes 38 claims broadly covering compositions, methods, uses, and systems for double-stranded RNAs."

The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.